Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:28 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
NCT02959437 · Incyte Corporation · PHASE1/PHASE2 · terminated · last registry update 2025-10-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study terminated by Sponsor” | – | Registry record, Incyte Corporation |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDCD1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-21Also stopped (terminated): Merck Sharp & Dohme LLC, MK-1484 + Pembrolizumab (NCT05382325)
- 2026-10-21Results posted on the registry: Floor Backes, MD, Lenvatinib + Paclitaxel (NCT04781088)
- 2026-10-20Also stopped (suspended): Mayo Clinic, Emavusertib + Pembrolizumab (NCT05669352)
- 2026-10-20Results posted on the registry: Diwakar Davar, Dostarlimab (TSR-042) (singly) + Dostarlimab (TSR-042) and TSR-022 (combination) (NCT04139902)
- 2026-10-20Also stopped (suspended): City of Hope Medical Center, Decitabine + Pembrolizumab (NCT03969446)
- 2026-10-19Also stopped (suspended): National Cancer Institute (NCI), a drug against PDCD1 (NCT04866810)
- 2026-10-09Phase 3 first posted: UNC Lineberger Comprehensive Cancer Center, anti-PD1 agent therapy - 1 year + anti-PD1 agent therapy - 2 years (NCT07867002)
- 2026-09-30Results posted on the registry: M.D. Anderson Cancer Center, Pembrolizumab + Romidepsin (NCT03278782)
- 2026-09-21Phase 3 first posted: Merck Sharp & Dohme LLC, Sac-TMT + Pembrolizumab and Berahyaluronidase alfa (NCT07829783)
- 2026-09-21Results posted on the registry: Roswell Park Cancer Institute, Pembrolizumab (NCT04032418)
- 2026-08-20Phase 3 first posted: Revolution Medicines, Inc., zoldonrasib + Placebo (NCT07777822)
- 2026-08-10Phase 3 first posted: AbbVie, ABBV-1480 + Pembrolizumab (NCT07756645)
- 2026-08-07Results posted on the registry: Robert Haddad, MD, 9-ING-41 + Carboplatin (NCT05010629)
- 2026-07-27Results posted on the registry: Medical College of Wisconsin, Cemiplimab + Paclitaxel (NCT04243616)
- 2026-07-20Phase 3 first posted: AIO-Studien-gGmbH, Tislelizumab + Tislelizumab Combined With Chemotherapy (NCT07715396)
- 2026-07-06Phase 3 first posted: GlaxoSmithKline, Mocertatug rezetecan + Dostarlimab (NCT07684599)
- 2026-06-29Phase 3 first posted: Astellas Pharma Global Development, Inc., ASP2138 + Pembrolizumab (NCT07673887)
- 2026-05-15Phase 3 first posted: Guangzhou Virotech Pharmaceutical Co., Ltd., VRT106 + VRT106 in combination with camrelizumab and apatinib (NCT07589244)
- 2026-05-11Phase 3 first posted: Pfizer, PF-08634404 + Pembrolizumab (NCT07578649)
- 2026-05-04Phase 3 first posted: Astellas Pharma Global Development, Inc., Enfortumab vedotin + Cisplatin (NCT07566156)
- 2026-04-21Phase 3 first posted: Hoffmann-La Roche, Divarasib + Pembrolizumab (NCT07541170)
- 2026-04-07Phase 3 first posted: Merck Sharp & Dohme LLC, Intismeran + Pembrolizumab coformulated with berahyaluronidase alfa (NCT07513376)
- 2026-03-09Phase 3 first posted: First Affiliated Hospital of Guangxi Medical University, Becotatug Vedotin + Sintilimab (NCT07459296)
- 2026-02-27Results posted on the registry: M.D. Anderson Cancer Center, Lenalidomide + Pembrolizumab (NCT02446457)
- 2026-02-25Phase 3 first posted: Merck Sharp & Dohme LLC, Calderasib + MK-3475A (NCT07431827)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision